Results 91 to 100 of about 82,604 (202)

SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. [PDF]

, 2019
de novo fatty acid biosynthesis (DNFA) is a hallmark adaptation of many cancers that supports survival, proliferation, and metastasis. Here we elucidate previously unexplored aspects of transcription regulation and clinical relevance of DNFA in cancers ...
Näär, Anders M, Wu, Su
core  

Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis

Frontiers in Pharmacology
AimCutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared ...
Junhui Qian, Jinlong Wan, Qin Yao, Yin Chen, Tao Ling, Yuejuan Zhang, Zhihua Tang   +6 more
doaj   +1 more source

Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors

Chinese Journal of Lung Cancer, 2016
In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer (NSCLC), drugs targeting epidermal growth factor receptor (EGFR) has been widely used in clinical practice, it is of milestone significance.
Xiaoyan KANG, Nan ZHU, Xia SONG
doaj   +1 more source

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx

Oral Oncology Reports
Locoregionally advanced mucosal melanoma, particularly when harboring the BRAF V600L mutation and situated in the hypopharynx, presents a therapeutic challenge due to limited treatment options and aggressive behavior.
Sivakamavalli Jeyachandran
doaj   +1 more source

The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review. [PDF]

Cureus, 2023
Malakar A, Kumar VR, Yadav P, Bhardwaj V, Barua CG, Bhardwaj G.   +5 more
europepmc   +1 more source

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. [PDF]

J Clin Invest, 2023
Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.   +13 more
europepmc   +1 more source

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature. [PDF]

Cancers (Basel), 2023
Guerrero P, Albarrán V, San Román M, González-Merino C, García de Quevedo C, Moreno J, Calvo JC, González G, Orejana I, Chamorro J, Martínez-Delfrade Í, Morón B, de Frutos B, Ferreiro MR.   +13 more
europepmc   +1 more source

Molecular strategies in BRAF targeting: advances in patents, structure activity relationship and future prospects

Medicine in Drug Discovery
BRAF, a serine or threonine protein kinase, plays a crucial role in the MAPK/ERK signaling pathway and is implicated in various malignancies, including melanoma, colorectal, lung, thyroid, and hematologic cancers. The V600E mutation is the most prevalent
Purabi Saha, Jugnu Goyal, Shammy Jindal, Vikramdeep Monga, Kamya Goyal   +4 more
doaj   +1 more source

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022. [PDF]

ACS Omega, 2023
Singh AK, Sonawane P, Kumar A, Singh H, Naumovich V, Pathak P, Grishina M, Khalilullah H, Jaremko M, Emwas AH, Verma A, Kumar P.   +11 more
europepmc   +1 more source

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer

Molecular Cancer
Background BRAF activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis in part due to an inferior response to standard chemotherapy.
Christopher A. Ladaika, Averi Chakraborty, Ashiq Masood, Galen Hostetter, Joo Mi Yi, Heather M. O’Hagan   +5 more
doaj   +1 more source